Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study

Journal:
Blood
Published:
Affiliations:
22
Authors:
22
Institutions Authors Share
Gilead, United States of America (USA)
6.000000
0.27
UNC Lineberger Comprehensive Cancer Center, United States of America (USA)
1.000000
0.05
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)
1.000000
0.05
Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole), France
1.000000
0.05
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
0.05
Royal Adelaide Hospital (RAH), Australia
1.000000
0.05
University Hospital of Munich (KUM), LMU, Germany
1.000000
0.05
Bern University Hospital, Switzerland
1.000000
0.05
University of Chicago Comprehensive Cancer Center, United States of America (USA)
1.000000
0.05
Sidney Kimmel Cancer Center (SKCC), TJU, United States of America (USA)
1.000000
0.05
Calvary Mater Newcastle, Australia
1.000000
0.05
University of Yamanashi Hospital, Japan
1.000000
0.05
Sant'Orsola Malpighi Hospital, Italy
1.000000
0.05
University College London Hospitals NHS Foundation Trust (UCLH), United Kingdom (UK)
1.000000
0.05
La Fe University Hospital, Spain
0.500000
0.02
University of Valencia (UV), Spain
0.500000
0.02
Queen Mary Hospital (QMH), China
0.333333
0.02
The University of Hong Kong - Shenzhen Hospital (HKU-SZH), China
0.333333
0.02
Hong Kong Sanatorium and Hospital (HKSH), China
0.333333
0.02
Oxford MRC Weatherall Institute of Molecular Medicine (WIMM), United Kingdom (UK)
0.333333
0.02
John Radcliffe Hospital, United Kingdom (UK)
0.333333
0.02
Oxford University Hospitals NHS Trust (OUH), United Kingdom (UK)
0.333333
0.02